|
EQS-News: Defence Therapeutics Inc.
/ Key word(s): Study
_ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S SUCCESSFULL STUDY ON THE ACCUVAC-PT007 VACCINE TARGETING CERVICAL CANCER
Vancouver, BC, Canada, November 23th, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice (“GLP”) studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer. GLP studies conducted on rodents demonstrate a full spectrum of safety and tolerability with no signs of complications. Cervical cancer normally occurs when epithelial cells of the cervix are infected with the human papillomavirus (HPV), one of the most common sexually transmitted disease. Although HPV infections can resorb, infections escaping the immune system ultimately led to genital warts leading to advanced cancers that are hardly treated with standard of care. Currently, vaccination targeting HPV directly can protect from cervical cancer. However commercially available vaccines (containing a mix of 9 HPV-derived L1 proteins) are not designed to protect from all HPV subtypes and the vaccine on the market cannot be used to treat pre-established cervical cancer. Defence focused on this "gap" by engineering AccuVAC-PT007, a protein-based vaccine containing a single oncoprotein (E7) linked to AccumTM for enhanced antigen presentation by the immune system. This vaccine can not only be used to protect from HPV (prophylactic use), but it is the only experimental vaccine capable of curing established cervical cancer when combined to immune-checkpoint inhibitors. The AccuVac may be a solution. Using the AccumTM platform, Defence developed the AccuVAC-PT007, a protein-based vaccine targeting the E7 oncoprotein of the HPV virus. AccuVAC-PT007 was previously shown to provide complete protection against cervical cancer (prophylactic vaccination) as shown in our press release dated on May 17, 2022. These ground-breaking observations led to the testing of AccuVAC-PT007 as a treatment with pre-established cervical cancer (therapeutic vaccination). Pre-clinical studies conducted on rodents, as reported in our press release dated on June 27, 2022, showed that the co-delivery of AccuVAC-PT007 with several immune-checkpoint blockers (anti-PD-1, anti-CTLA4 or anti-CD47) lead to potent control of tumor growth with a more pronounced effect observed with anti-CD47, one of the latest immune-checkpoint blockers undergoing clinical development. "The successful completion of the GLP studies clearly demonstrate the safety and tolerability profile of our AccuVAC-PT007 vaccine. With only one oncoprotein (E7) linked to our AccumTM, we would significantly reduce the manufacturing cost and more importantly our vaccine would have the capacity to cure established cervical cancer. It is another strong example of Defence’s AccumTM technology versatility. And it also shows how dedicated we are in developing efficiently vaccines to eradicate tumors. Our AccuVAC-PT007 vaccine is now ready for a Phase I Clinical Trial or partnership/licence with a Pharma", adds Mr. Plouffe, the CEO of Defence Therapeutics. Besides cervical cancer, HPV can cause cancer of the vulva, vagina, penis, or anus. It can also cause cancer in the back of the throat (called oropharyngeal cancer) and can include the base of the tongue and tonsils. In addition, patients with weak immune systems may be unable to fight off a given HPV infection, which brings forward another important ailment with unmet medical needs. This is an opportunity for the AccuVAC-PT007 that Defence has developed. https://www.prnewswire.com/news-releases/global-cervical-cancer-treatment-market-size-expected-to-reach-11-billion-by-2027-301642056.html#:~:text=A%20report%20from%20360ResearchReports%20projected,USD%2011117.68%20million%20by%202027 About Defence: Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272 Splouffe@defencetherapeutics.com
Cautionary Statement Regarding “Forward-Looking” Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
23.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Defence Therapeutics Inc. |
| 1680 - 200 Burrard St | |
| V6C3L6 Vancouver | |
| Canada | |
| E-mail: | info@defencetherapeutics.com |
| Internet: | https://defencetherapeutics.com |
| ISIN: | CA24463V1013 |
| WKN: | A3CN14 |
| Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
| EQS News ID: | 1494069 |
| End of News | EQS News Service |
|
|
1494069 23.11.2022 CET/CEST
